Vir Biotechnology (VIR) Free Cash Flow (2018 - 2026)

Vir Biotechnology has reported Free Cash Flow for 9 years, with the latest figure at -$132.8 million in Q1 2026.

• Quarterly Free Cash Flow fell 66.5% year-over-year to -$132.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$449.6 million (down 6.52% YoY) and the FY2025 annual result came in at -$396.6 million, up 12.57% from the prior year.
• Free Cash Flow declined to -$132.8 million in Q1 2026 per VIR's latest filing, from -$26.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $939.5 million in Q2 2022 and troughed at -$398.7 million in Q2 2023.
• A 5-year average of -$11.1 million and a median of -$109.5 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow soared 694.22% in 2022, then sank 585.38% in 2023.
• Over 5 years, Free Cash Flow stood at $22.6 million in 2022, then tumbled by 585.38% to -$109.5 million in 2023, then grew by 18.12% to -$89.6 million in 2024, then surged by 70.74% to -$26.2 million in 2025, then tumbled by 406.31% to -$132.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$132.8 million, -$26.2 million, and -$167.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.